Neurology · DepressionRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for SPRAVATO (Esketamine Hydrochloride)

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen36 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/10/2026, 6:00:16 AM

Assessment confidence: 54% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's acceptance of the supplemental application for SPRAVATO signifies a potential label expansion, which could strengthen Janssen's position in the competitive landscape of depression therapies. This development warrants close monitoring as it may influence market dynamics and sales forecasts. Regulatory context from FDA (FDA AP — SPRAVATO (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should evaluate the potential impact of this supplement on SPRAVATO's market positioning and future sales forecasts. The strongest clinical anchor is Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression (ClinicalTrials.gov), entity match (spravato). In Neurology · Depression, 7 regulatory and 5 competitive items passed relevance filtering for Janssen Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts Supplemental Application for Concerta by Janssen. This acceptance may enhance Janssen's competitive position in the depression treatment market, particularly against other novel therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SPRAVATO (SUPPL) (FDA). Entity match (spravato). The acceptance of the supplemental application indicates a pathway for potential label changes, which could affect compliance and marketing strategies.

Key Risks

Elevated medium regulatory exposure for Janssen Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, the label expansion could lead to increased market share for SPRAVATO, impacting revenue positively in a competitive market.
Portfolio teams should evaluate the potential impact of this supplement on SPRAVATO's market positioning and future sales forecasts.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's decision on the supplemental application and any subsequent label changes.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SPRAVATO (SUPPL)
FDAhigh relevance
Entity match (spravato)
FDA document
View source
FDA AP — SPRAVATO (SUPPL)
FDAhigh relevance
Entity match (spravato)
FDA document
View source
FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression
ClinicalTrials.govhigh relevance
Entity match (spravato)
FDA document
View source
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
tDCS: Sleep to Mood in Depression (S2M-D)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Reducose on Postprandial Glycemic Levels in Obese Children and Adolescents
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Accepts Supplemental Application for Concerta by Janssen
Humanexa Signalsmedium relevance
Moderate corpus alignment
Alembic's Duloxetine Hydrochloride Supplement Receives AP Status from FDA
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Accepts Supplement Application for Artesunate by Amivas
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Influencing factors of oral frailty in Chinese maintenance hemodialysis patients: Bayesian network analysis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen Pharmaceuticals
SPRAVATO
depression treatment market

Commercial impact

medium

If approved, the label expansion could lead to increased market share for SPRAVATO, impacting revenue positively in a competitive market.

Regulatory impact

medium

The acceptance of the supplemental application indicates a pathway for potential label changes, which could affect compliance and marketing strategies.

What to watch

Monitor the timeline for the FDA's decision on the supplemental application and any subsequent label changes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.